



# Annual Report

2022/2023





# ACKNOWLEDGMENT OF COUNTRY

In the spirit of reconciliation, FOP Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community.

We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples.

In recognition that we operate in Australia & New Zealand, FOP Australia acknowledges Māori as tangata whenua and Treaty of Waitangi partners in Aotearoa New Zealand.

# Contents

<b>Overview of FOP Australia</b>	4
<b>Organisational Aims</b>	4
<b>2022-2023 Board of Directors</b>	5
<b>Chairpersons Report</b>	5
<b>Treasurer's Report</b>	8
<b>IFOPA International Presidents Council Report</b>	9
<b>Medical Report</b>	10
<b>Acknowledgements and Contact Details</b>	13
<b>Community Acknowledgements</b>	13
<b>Fundraiser Acknowledgements</b>	13
<b>FOP Australia: How you can help</b>	13
<b>FOP Australia: Contact Us</b>	14
<b>Appendix 1: Financial Statements</b>	15
<b>Statement of Profit or Loss and other comprehensive income</b>	15
<b>Statement of Financial Position</b>	16
<b>Statement of Cash Flows</b>	17
<b>Appendix 2: Notes to Financial Statements</b>	18
<b>Appendix 3: Directors Declaration</b>	20

Cover photos:

- Tyson Stanley and supporters at his 2022 Footy for FOP day in Somerville Victoria
- Jack Fegan with some of his photography, as featured in the 2023 Wildlife Photography Calendars
- Damian Jones with parents and Cathy and Howard celebrating his birthday with family and friends
- Naomi Scott participating in RunMelbourne on behalf of FOP Australia

## Overview of FOP Australia

FOP Australia was established in 2015, with the first Annual General Meeting held in Brisbane in May that year. FOP Australia is registered with the Australian Charities and Not-for-profits Commission (ACNC) as a charity with Deductible Gift Recipient (DGR) status through the Australian Tax Office. This organisation is a company limited by guarantee; we have a board of directors and are accountable to our members. We have no paid employees and run purely through volunteers.

Through links with the [International FOP Association \(IFOPA\)](#), we aim to improve the lives of individuals and families affected by FOP by:

- Raising awareness of FOP
- Providing a support network for families and individuals with FOP
- Furthering research towards treatment and a cure

With the FOP research effort entering the clinical trial phase, in late 2018 the board mapped out an [Advocacy Strategy](#) for the charity to guide future strategic planning. You can read more about the development of the strategy [here](#).

In working towards these goals, we are inspired by the work of the international FOP community, and are so grateful for the support of FOP champions

## Organisational Aims

### ***Advocacy***

Advocate for people with FOP in Australia and New Zealand to have access to any effective FOP therapies, including subsidised funding of therapies

### ***Fundraising***

Provide a significant proportion of our fundraising to advances in research into treatments and/or a cure for FOP.

### ***Build and Maintaining links with Medical Community***

Build and maintain links with the medical community, including clinicians in Australia and New Zealand and internationally to understand new developments in medical research and its potential application to people with FOP.

### ***Build and Maintaining strong links with FOP Research***

Build and maintain links with the medical community, including clinicians in Australia and New Zealand and internationally to understand new developments in medical research and its potential application to people with FOP.

### ***Build and Maintaining Strong Links with the International Community***

Build and maintain strong links with those undertaking FOP research, including academic centres and pharmaceutical companies.

### ***Establishing and Improving the function of FOP Australia***

To establish and improve the function of FOP Australia as a representative and supportive organisation for the FOP community of Australia and New Zealand.

## **2022-2023 Board of Directors**

Talia Wilson (Chairperson)

Jo McAlpine

Emma Atkin

Lauren Gibson

Lydia Scott

## **Chairpersons Report**


### **Reflecting on the Year**

As we take a moment to review the past year, we find ourselves celebrating yet another successful year of leading FOP Australia. It's heartening to witness our support base steadily expanding. Within our community, individuals living with FOP and their families have been actively reaching out to their local communities, fostering connections that not only contribute to fundraising efforts but also play a crucial role in spreading much-needed awareness about FOP and the work of FOP Australia.

### **Our Successes**

#### **Funds Raised**

Our ability to consistently raise funds remains a cornerstone of our organization, enabling us to make substantial contributions to IFOPA's ongoing research initiatives and sustain our well-established programs. In addition, we have been steadily contributing towards our dedicated fund aimed at supporting our future patient gathering. This year's funds will further add to each of these programs.



Research – 50% (IFOPA gene therapy, IFOPA ACT for FOP grants, University of Pennsylvania): \$22,497

Patient gathering fund: \$10,686.09

Support activities (includes grants): \$10,686.09

Operational costs - 5%: \$1,124.85

### International research initiatives

FOP Australia maintains its collaborative partnership with IFOPA, an organization renowned for its expertise and extensive resources in managing effective research endeavours. In the year 2023, we are proud to announce that we have continued our commitment to IFOPA's "In Pursuit of a Cure" campaign and ACT for FOP grants with a substantial contribution totalling \$17,497. Additionally, we are delighted to repeat our \$5,000 annual contribution to the University of Pennsylvania. This contribution plays a pivotal role in advancing research efforts to gain a deeper understanding of the disease process and identify potential treatment targets. For further details, our medical representative, Lydia, has provided comprehensive information in the medical report. Please note that regulations limit our organisation to sending no more than 50% funds raised internationally, which guides our determination of the annual contribution to the international research effort.

### Advancements in Treatment

It is exciting to report that there are currently three drug trials being offered right here in Australia, showcasing significant progress in our pursuit of improved treatments for FOP. To ensure our community is well-informed about these trials and their potential impact, we recently hosted an information evening dedicated to discussing the ongoing research opportunities. It was heartening to see so many of you in attendance, and I hope the evening provided valuable insights. For those seeking more detailed information about these trials, Lydia, our medical representative, has shared comprehensive insights in her medical report. As always, please don't hesitate to reach out to us if you have any questions or require further information. We are here to support you every step of the way.

### Celebrating International Clinical Trials Day

I would like to extend our heartfelt gratitude to Lauren Dean and the Fegan family for representing FOP Australia at the International Clinical Trials Day held at Royal North Shore Hospital. Their presence at this event was truly appreciated as they shared their invaluable insights into FOP. Their participation highlights the dedication of our community in raising awareness about FOP and the importance of clinical trials. Thank you, Lauren and the Fegan family, for your commitment to our cause and for being wonderful ambassadors for FOP Australia at this important event.

### The Success of the Oliver Collins Education Grant

We are delighted to report the resounding success of the Oliver Collins Education Grant, which was introduced for the first time this year in honour of Ollie Collins. This grant has been specifically designed to provide assistance to individuals with FOP in their endeavours to advance their education, whether in formal academic pursuits or personal hobbies. The enthusiastic response to this initiative has been heartwarming, reflecting our community's commitment to continuous learning and personal growth. The Oliver Collins Education Grant has not only provided financial support but has also served as a source of inspiration for individuals to pursue

their educational dreams. We are immensely proud of the achievements of our grant recipients and look forward to nurturing more educational aspirations in the future, all in memory of the remarkable Ollie Collins.

### **Celebrating Successful Fundraisers**

This year has seen an array of successful fundraising initiatives that highlight the unwavering commitment and creativity within our FOP Australia community. From ongoing sock sales that have been a consistent source of support throughout the year to Tyson Stanley's spirited football day, which brought us all together for a fun-filled event with a meaningful purpose. We were also fortunate to have Jack and the Fegan family's incredible calendars, featuring Jack's captivating photography, which not only raised funds but also showcased the artistic talents within our community.

What's truly inspiring is the diverse range of ideas that individuals have come up with to raise funds, reflecting the unique spirit of our community.

The success of these endeavours underscores the collective dedication to supporting FOP Australia's mission, and we are immensely grateful to everyone who contributed, organized, or supported these initiatives. Your enthusiasm and innovation continue to be a driving force behind our progress, and we look forward to more exciting fundraising ventures in the future. Thank you for your unwavering support.

### **Thank you**

I would like to take a moment to express deep gratitude to Emma Atkin for her invaluable contributions to FOP Australia. Emma came to us after her husband spent time working with Tyson Stanley and her contributions have played a pivotal role in driving FOP Australia forward. As Emma steps down from her role, we want to acknowledge and appreciate her unwavering support of our mission and her contributions to our organization's growth and success. Thank you, Emma, for your exceptional service and dedication.

## **Looking to the Year Ahead**

### **Patient Gathering**

I am excited to share that we have initiated the planning process for an upcoming patient gathering in the year ahead. To steer this endeavour, we have assembled a dedicated team of four individuals who have generously volunteered their time and expertise. I would like to extend my heartfelt thanks to these individuals for their unwavering commitment to making this gathering a reality.

Our initial plans are taking shape, and we are looking to hold this gathering in the next 12 to 18 months. We understand the importance of tailoring this event to meet the diverse needs and preferences of our community. To achieve this, we will be sending out a survey soon to gather valuable insights from all of you. Your input will be invaluable in helping us design an inclusive and meaningful gathering that caters to as many individuals as possible. Stay tuned for the survey, and let's work together to create an unforgettable experience for our FOP community.

### **Success comes from you**

Every year I am filled with a profound sense of gratitude and pride. This year is no different. This has been a year marked by resilience, dedication, and noteworthy achievements within the FOP Australia community.

We have witnessed our support base grow, embarked on successful fundraising endeavours, expanded our horizons with the Oliver Collins Education Grant, and navigated the challenges of an ever-evolving landscape. Our commitment to serving individuals and families affected by Fibrodysplasia Ossificans Progressiva (FOP) remains steadfast.



I want to extend my sincere thanks to each member, volunteer, supporter, and contributor who has played a role in our success. Your unwavering dedication and creative initiatives continue to drive us forward.

As we look ahead, our resolve remains strong. We are determined to advance research, support individuals and families, and raise awareness about FOP. The future holds exciting possibilities, and together, we will shape it to be even brighter. Thank you all for being an integral part of our journey. Your passion and commitment inspire us daily. Together, we will continue to make a meaningful impact on the lives of those living with FOP.

Warm regards,

**Talia Wilson, Chairperson**

## Treasurer's Report

I am delighted to connect with you today via our annual report, on behalf of our Treasurer, Emma Atkin, and bring you this report, providing you with a look into our financial landscape for the fiscal year 2022/2023.

This past year has been a wonderful journey, collaborating closely with our exceptional team and being an integral part of the incredible achievements we've accomplished.

With great pleasure, I now present you a detailed and comprehensive overview of FOP Australia's financial status. This report encapsulates our financial statements for the year ending on June 30, 2023. This overview includes:

- A breakdown of our income and expenditures over the past fiscal year.
- A detailed account of our assets and liabilities during this same period.

Please find attached the 2022-2023 Statement of Financial Position, Statement of Profit and Loss, and Statement of Cash Flows. These documents reveal that FOP Australia achieved an income of \$44,993 for the 2022/2023 financial year. As of June 30, 2023, our organization boasted equity amounting to \$137,839. Thanks to the unwavering support and relentless fundraising efforts of FOP Australia and its dedicated members, we were able to contribute \$5,000 to the Shore Lab at the University of Pennsylvania and a total of \$17,497 towards projects supported by IFOPA. The remainder of our fundraising endeavours has been allocated to bolster our support activities (\$11,248) and prepare for our forthcoming patient gathering (\$11,248). It has been heartening to note that we have sustained the support of our loyal donors who have successfully organized and contributed to some remarkable online fundraising events.

FOP Australia continues to maintain a sturdy financial foundation, positioning us well to further amplify our fundraising capabilities to meet both our immediate and future financial commitments. We are eagerly looking forward to launching innovative and exciting initiatives that will make the best use of these funds, thereby enhancing our support for the FOP community and maintaining our existing support structures. Among these endeavours is our upcoming patient gathering, a new project that holds great promise.

Our primary sources of income, continues to comprise of pod fundraisers and individual donations. It's been immensely gratifying to witness our base of supporters expand, with each individual contributing to fundraising efforts in their own unique and creative ways. We deeply appreciate every person's dedication, recognizing that their contributions go beyond fundraising, also encompassing the invaluable role of raising awareness with each event they undertake.



Our expenses have been prudently managed, with only a slight increase compared to the previous year, largely driven by our expanding online presence. We anticipate that these expenses will remain stable during the 2023-2024 financial year, with no significant variances anticipated. Additionally, it's worth noting that our financial planning includes the added expense of our upcoming patient gathering, which will be carefully budgeted for while ensuring our continued financial stability.

In closing, I extend my heartfelt appreciation to all of you for your unwavering support.

In the interest of transparency, please note; three illegal transactions were carried out in the 2022/2023 financial year totalling \$3,499. All monies illegally removed were returned upon follow up with NAB, although quite delayed for the final transaction. The amounts are included in the totals seen throughout the financial documents, in particular, the 'Conference and fundraising' and 'Other' overheads seen in the Statement of Profit and Loss, as well as 'Receipts from customers' and 'Unapproved transactions' found in the Statement of Cash Flows. There has been a delay in the restructure of our accounts and changeover of provider, however, we have made progress and will be implementing these new structures in the coming financial year.

**Talia Wilson, Chairperson**

## IFOPA International Presidents Council Report

The International Presidents Council (IPC) is a network of volunteers from around the world who work together to keep our community connected and informed. We meet regularly throughout the year and discuss several topics such as trial information, FOP gatherings around the world, and how we can better meet the needs of the community. Please see below for an update on some of the international activities held in FY 23.

The IFOPA held their annual “In pursuit of a Cure” campaign in September 2022. This was the third year of the campaign with the theme “Investing in Every Path to Hope”. Updates on gene therapy and clinical trials were provided with fund raising at this critical time for FOP research being a key component of the campaign. I was lucky to be one of several FOP community ambassadors involved in the campaign, if you missed seeing the event you can re-watch it at this [link](#)

In October 2022, the IFOPA hosted a virtual Family Gathering which was well attended by the community. Family gatherings give the community the opportunity to come together, discuss a range of topics and connect with others from around the globe. They are generally held annually and often have a virtual component allowing people to join around the world. If you are unable to attend due to the time zone difference, it is worth registering for the event which gives you the ability to rewatch some sessions at a later time.

FOP Awareness Day in April is a global event. Planning for this involves IPC representatives and FOP community members and starts months in advance. 15 organisations representing 20 countries from around the world came together in 2023 to celebrate the day and raise awareness during the month of April. We are grateful to the IFOPA for bringing us together to celebrate the discovery of the FOP gene and helping to raise ongoing awareness of FOP.

The IFOPA provide many services for the FOP community, see below for some helpful links:

- Youtube – There are several presentations on a range of topics <https://www.youtube.com/@IFOPA>

- Ability Toolbox – helps to empower individuals with FOP by promoting independence through the use of tools and home adaptations. I highly recommend reading more at the link below. [https://www.ifopa.org/ability\\_toolbox\\_program](https://www.ifopa.org/ability_toolbox_program)
- Resilient Living Program – focuses on the emotional well-being of families, including siblings, caretakers, spouses, and partners. [https://www.ifopa.org/resiliency\\_program](https://www.ifopa.org/resiliency_program)
- Advocacy Series - Podcasts, webinars and community panels for a range of topics. [https://www.ifopa.org/advocacy\\_series\\_2022](https://www.ifopa.org/advocacy_series_2022)
- Medical treatment guidelines are available at this link, including resources on covid-19. [https://www.ifopa.org/for\\_medical\\_professionals](https://www.ifopa.org/for_medical_professionals)

I look forward to bringing you further updates from the international community.

**Brooke Scott, IPC Representative**

## Medical Report

The 2022/2023 year has seen a range of developments in FOP research. Several potential therapies for FOP are being explored, and are at different stages of development and approval. This includes three drugs that have active trials open for enrolment in Australia (for patients from Australia and New Zealand). Although there are now many academic centres and pharmaceutical companies involved, progress of FOP research continues to be driven by people with FOP themselves (including Aussies and Kiwis!), with ongoing support through trial enrolment, FOP Registry contributions, patient/researcher engagement activities, and of course through fundraising and raising awareness. This report contains a summary of the main developments over this period, with some references attached for people interested in further reading.

---

Ipsen published the result of the Phase III clinical trials of **palovarotene** in January 2023, summarising the outcome of the 99 individuals with FOP who enrolled in this study and contributed to this vital step in the global research effort, the first ever phase III trial of a potential FOP treatment. As described in the [plain language summary publicly available online in Future Medicine](#), the study showed that palovarotene may reduce extra bone formation outside of the normal skeleton, side effects demonstrated included very common skin problems, and a serious side effect called premature growth plate closure in younger patients (<14years old). Ipsen continues to seek regulatory approvals for palovarotene in different regions and countries, and outcomes so far have been variable. In May, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use recommended the European Commission should not approve palovarotene as a treatment for FOP, based on the outcomes from clinical trials. On the 29<sup>th</sup> June, the United States Food and Drug Administration (FDA) advisory committee determined that the benefits of palovarotene outweigh the risks for FOP patients. The FDA will determine whether palovarotene will become the first FDA-approved treatment for FOP in August 2023. (*Update Sept 2023: The FDA approved palovarotene for treatment of FOP in USA. Ipsen have now submitted an application for TGA approval in Australia. Ipsen have not yet determined whether they will apply for registration in New Zealand.*)

The Regeneron OPTIMA phase III clinical trial of **garetosmab** (an activin-A antibody) continues and is now recruiting in Australia at Royal North Shore Hospital (RNSH) in Sydney. This follows the publication of the [phase II trial \(LUMINA\)](#) for this drug. This was one of **three enrolling clinical trials** discussed in an online community meeting hosted by the RNSH clinical trials team and FOP Australia in June. The other two trials enrolling through RNSH are the Incyte phase II PROGRESS trial of **kinase inhibitor INCB000928** and Clementia's FALKON trial of **kinase inhibitor IPN60130**. A key message from that discussion is that if you are interested in enrolling

any of these trials, but are not sure if you should, or not sure if you are eligible (or even if you think you are not eligible but would like to know for sure) please contact the trials team to explore your options. As Dr Rory Clifton-Bligh explained during the online discussion, the RNSH researchers are not there to pressure anyone in to enrolling into any trial at all, and just want people with FOP to have options available. So please reach out to the RNSH clinical trials team if you have any questions or wish to discuss your particular situation at [NSLHD-EndocrineResearch@health.nsw.gov.au](mailto:NSLHD-EndocrineResearch@health.nsw.gov.au). (Further information on all of the trials can be found on [clinicaltrials.gov](https://clinicaltrials.gov), or via the RNSH team). RNSH also continues the palovarotene follow-up study, **PIVOINE**, for local patients who were enrolled in the MOVE trial. The PROGRESS trial is also enrolling at Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne. The FALKON study is also enrolling at Westmead Children's Hospital, Sydney.

Research into how **gene therapy** could treat FOP continues through the University of Massachusetts in the USA, supported by funding from IFOPA including contributions from FOP Australia. This is a longer-term project and so far the team have demonstrated in mouse studies that gene therapy using recombinant viral vectors can deliver healthy genes and silence the pathways that cause bone formation. Detail of this is [available online in Nature Communications](#). If this work can continue to progress this may identify very promising therapeutic options. Because the research work is in a very early stage, the work remains reliant on fundraising from the global FOP community to continue, and FOP Australia are proud and grateful to provide some of that support via the IFOPA In Pursuit of a Cure Campaign since 2020.

There are several other research projects ongoing into **other potential therapies**, including saracatinib (in the STOPFOP trial in Europe), rapamycin (being studied by Kyoto University) and the study of KER-047 by Keros Therapeutics. In November 2022, BioCryst Pharmaceuticals announced that they would not be pursuing further development of their kinase inhibitor, noting that several other drugs of this kind were already undergoing trials. This reflects the challenges that the international FOP community face, as the rare nature of FOP means that there are limited patients that can enrol in trials, limiting the number of trials that are possible.

The low number of FOP patients available to potentially enrol in trials also makes it important that future trials are as well-designed as possible, in order to get the most accurate and helpful information about whether the drug being tested is both safe and effective. Many of the projects that the IFOPA have facilitated in recent years (including the Biobank, Mouse Model, Pre-Clinical Drug Testing Program) have gained information that will help guide future trials to get maximum possible benefit for patients. One of the most significant ongoing projects that can help future trials be designed well is the FOP Registry.

The **FOP Registry** continues to construct a more comprehensive understanding of what FOP is and does. This registry has been built up by people with FOP and continues to become more important through their ongoing contributions. The information collected will continue to help clinicians and researchers understand the disease, and have better information on how to design effective trials and improve clinical care. My personal opinion is that this is the most important current FOP research project, and I encourage everyone in Australia and New Zealand with FOP to consider enrolling, and to continue to add their information. People can participate in the registry even if also participating in trials, and regardless of the activity or severity of their FOP. You can learn more at [www.ifopa.org/fopregistry](http://www.ifopa.org/fopregistry). If you have questions or need help with any aspect of participating in the registry, please reach out via [info@fopaaustralia.org](mailto:info@fopaaustralia.org), via [help@fopregistry.org](mailto:help@fopregistry.org). Our IFOPA International Presidents' Council representative Brooke Scott is also happy to be contacted (via FOP Australia) to discuss her experience of participating in the registry. (And remember that IFOPA have arranged for a \$25USD electronic gift card for every survey completed!).

The Ipsen **Burden of Illness Study** was [published in September 2022](#) using the contributions of 405 individuals from around the world, including Australia and New Zealand, and containing comprehensive insights into the

realities of living with FOP. A **3-year natural history study** was also [published in September 2022 in Genetics in Medicine](#), collating data from 114 individuals with FOP. These projects both significantly increase the amount of real-life information about FOP available to treating doctors and to researchers. In addition to enrolling in research projects, people with FOP and their families continue to guide and motivate researchers in many other ways, including participating in **patient/researcher engagement activities**. Thank you to Laurin Dean and the Fegan family for attending International Clinical Trials Day at Royal North Shore Hospital, to help researchers understand more about FOP and why ongoing research for a treatment is so important. Also, during this year, people with FOP around the world made a vital contribution to helping the US regulatory approval body (the FDA) understand this disease by contributing written testimony about experiences of living with FOP; Thank you to those in our local community who contributed to that process.

---

It is getting harder to keep up with all the developments in FOP research, which is a good problem to have! Both FOP Australia and IFOPA try to share major news on social media. I recommend the IFOPA website as a source of further information about research news, particularly their FOP News section at <https://www.ifopa.org/fop-news> for ongoing updates. The IFOPA website also contains helpful resources for individuals and families considering enrolment in clinical trials. Clinicians treating people with FOP in Australia and New Zealand are encouraged to contact FOP Australia to be added to our list of contacts for research and treatment updates.

---

#### **Further reading (embedded links above):**

Pignolo et al. [The effects of palovarotene in patients with fibrodysplasia ossificans progressiva: a plain language summary](#). Future Rare Diseases 2023 3:1

Rocco et al. [Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial](#). medRxiv 2023.01.11.23284254; doi: <https://doi.org/10.1101/2023.01.11.23284254>

Yang, YS., Kim, JM., Xie, J. et al. [Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery](#). Nat Commun **13**, 6175 (2022). <https://doi.org/10.1038/s41467-022-33956-9>

Mukaddam et al. [The impact of fibrodysplasia ossificans progressiva \(FOP\) on patients and their family members: results from an international burden of illness survey](#) Future Rare Diseases 2022 2:4

Pignolo RJ, Baujat G, Brown M, et al. [The natural history of fibrodysplasia ossificans progressiva: A prospective 36-month study](#). Genetics in Medicine 2022,ISSN 1098-3600,<https://doi.org/10.1016/j.gim.2022.08.013>.

---

**Lydia Scott, Board Director / IFOPA Research Committee Member / General Medical Consultant (FRACP)**

## Acknowledgements and Contact Details

We would like to acknowledge the efforts of everyone who has supported our community over the last financial year.

### Community Acknowledgements

- Australian and New Zealand FOP patients and families
- FOP Australia members
- FOP Clinicians
- Fundraising Committee
- International FOP Association (IFOPA)
- Oliver Collins Education Grant selection panel members: Ellie and Will Collins, Ian Cali, Brooke Scott (and reserve selection panel volunteers Amanda Cali, Daniel Atkin and Alison McAlpine)
- Support Grant Program volunteers: Georgie Hyder, Dr Felicity Collins, Michelle Davis (IFOPA) and Jada Carr

### Fundraiser Acknowledgements

A special thank you to volunteers who have coordinated fundraiser events:

- Coffee Club
- FOP Awareness Socks and Shoelaces
- 2023 Wildlife Calendars
- Battery Collection
- Birthday Fundraisers
- Run Melbourne
- Entertainment books
- Charity Buy
- Wedding Gift Donations

## FOP Australia: How you can help

**Spread the word on Social Media:** follow us on Facebook, Twitter and Instagram. “Like” and share our posts

**Newsletter:** Encourage others to sign up as members online and share our quarterly newsletter with family and friends on Social Media

**Membership** for is \$10 per person per financial year and is free for those living with FOP or clinicians interested in learning more about FOP

**FOP Connection Registry:** If you or your child has FOP, please register on the FOP Connection Registry and update your data every 6 months.






**Fundraising:** Support our fundraising activities or even come up with your own fundraising ideas

**Corporate Partnership:** Become a Corporate Partner

**Donate money:** Direct donations through our website – all donations are tax deductible and are channelled toward our FOP community

**Donate your Time:** Donate your time to helping our community through leading a fund-raising event or consider joining our board

## FOP Australia: Contact Us

		<a href="https://fopaustralia.org/">https://fopaustralia.org/</a>
		<a href="mailto:info@fopaustralia.org">info@fopaustralia.org</a>
		<a href="https://www.facebook.com/FOPAustralia/">https://www.facebook.com/FOPAustralia/</a>
		<a href="https://twitter.com/fopaustralia">https://twitter.com/fopaustralia</a>
		<a href="https://www.instagram.com/fop_australia">https://www.instagram.com/fop_australia</a>

## Appendix 1: Financial Statements

### Statement of Profit or Loss and other comprehensive income

**FOP Australia**  
**ABN 51 603 200 871**  
**Statement of Profit or Loss and Other Comprehensive Income**  
**For the year ended 30 June 2023**

	Note	2023 \$	2022 \$
Conference and fundraising		48,494	70,208
<b>Gross Profit</b>		48494	70208
Donations to IFOPA		-25,559	-29,401
Donations to Upenn		-5,000	-5,060
Other		-7,699	-14,878
<b>Totals Overheads</b>		-38258	-49339
Profit before income tax		10236	20869
Income tax (credit) expense		10236	20869
<b>Profit for the year</b>		10236	20869
<b>Total comprehensive income for the year</b>		10,236	20,869



## Statement of Financial Position

**FOP Australia Ltd**  
**ABN 51 603 200 871**  
**Statement of Financial Position**  
**As at 30 June 2023**

	Note	2023 \$	2022 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash Assets		137,838	127,603
<b>Total Current Assets</b>		137,838	127,603
 <b>Total Assets</b>		 137,838	 127,603
 Net Assets		 137,838	 127,603
 <b>Equity</b>			
Retained Profits		127,603	106,734
Current Year Profit		10,236	20,869
<b>Total Equity</b>		<u>137,839</u>	<u>127,603</u>

## Statement of Cash Flows

**FOP Australia Ltd**  
**ABN 51 603 200 871**  
**Statement of Cash Flows**  
**For the year ended 30 June 2023**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
<b>Cash Flow from Operating Activities</b>		
Receipts from customers	48,494	70,208
Payments to suppliers and employees	-4,199	-5,790
Donations to IFOPA	-25,559	-29,401
Donations to Upenn	-5,000	-5,060
Unapproved transactions - money returned	-3,499	-9,088
 Net cash provided by (used in) operating activities	 10,236	 20,869
 Net increase (decrease) in cash held	 10,236	 20,869
 Cash at the beginning of the year	 127,603	 106,734
Cash at the end of the year	<u>137,839</u>	<u>127,603</u>

## Appendix 2: Notes to Financial Statements

**FOP Australia Ltd**  
**ABN 51 603 200 871**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

### **Note 1: Summary of Significant Accounting Policies**

FOP Australia Ltd is a company limited by guarantee, incorporated, and domiciled in Australia. The company is registered with the Australian Charities and Not for Profits Commission and holds Deductible Gift Recipient Status.

The financial statements were authorized for issue on 15th September 2023 by the directors of the company.

#### **Basis of preparation**

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users dependent on general purpose financial statements. The financial statements are therefore special purpose financial statements that have been prepared in order they meet the Collections Act 1966.

The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the Australian Charities and Not-for-profits Act 2012 and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with the previous period unless stated otherwise.

The financial statements, except for cash flow information have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes. The material accounting policies that have been adopted in the preparation of the statements are as follows:

#### **Accounting Policies**

- **Cash and cash equivalents**

Cash and cash equivalents include cash on hand and deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowing in current liabilities on the statement of financial position. <sup>2</sup>

- **Revenue and other income**

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed.

Interest revenue is recognized using the effective interest method which for floating rate financial assets is the rate inherent in the instrument.

Revenue recognition relating to the provision of services is determined with reference to the stage of completion of the transaction at the end of the reporting

period and where the outcome of the contract can be estimated reliably. Stage of completion is determined with reference to the services performed to date as a percentage of total anticipated services to be performed. Where the outcome cannot be estimated reliably, revenue is recognized only to the extent that related expenditure is recoverable.

## Appendix 3: Directors Declaration

**FOP Australia Ltd**  
**ABN 51 603 200 871**  
**Directors Declaration**

The directors of the company declare that:

- 1) The financial statements and notes:
  - (a) Comply with accounting policies described in Note 1 to the financial statements; and
  - (b) Give a true and fair view of the company's financial position as at 30 June 2023 and of its performance for the year ended on that date;
- 2) In the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Talia Wilson  
Chair

Date; 15 September 2023